Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia
Open Access
- 1 April 2013
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (4), 1756-1762
- https://doi.org/10.1128/aac.01232-12
Abstract
In a previous phase 3 study, the cure rates that occurred in patients with hospital-acquired pneumonia treated with tigecycline at the approved dose were lower than those seen with patients treated with imipenem and cilastatin (imipenem/cilastatin). We hypothesized that a higher dose of tigecycline is necessary in patients with hospital-acquired pneumonia. This phase 2 study compared the safety and efficacy of two higher doses of tigecycline with imipenem/cilastatin in subjects with hospital-acquired pneumonia. Subjects with hospital-acquired pneumonia were randomized to receive one of two doses of tigecycline (150 mg followed by 75 mg every 12 h or 200 mg followed by 100 mg every 12 h) or 1 g of imipenem/cilastatin every 8 h. Empirical adjunctive therapy was administered for initial coverage of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infection, depending on the randomization regimen. Clinical response, defined as cure, failure of treatment, or indeterminate outcome, was assessed 10 to 21 days after the last day of therapy. In the clinically evaluable population, clinical cure with tigecycline 100 mg (17/20, 85.0%) was numerically higher than with tigecycline 75 mg (16/23, 69.6%) and imipenem/cilastatin (18/24, 75.0%). No new safety signals with the high-dose tigecycline were identified. A numerically higher clinical response was observed with the 100-mg dose of tigecycline. This supports our hypothesis that a higher area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC ratio) may be necessary to achieve clinical cure in patients with hospital-acquired pneumonia. Further studies are necessary. (The ClinicalTrials.gov identifier for this clinical trial is NCT00707239.)Keywords
This publication has 23 references indexed in Scilit:
- Interleukin-6 in Sepsis and Capillary Leakage SyndromeJournal of Interferon & Cytokine Research, 2012
- Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with TigecyclineAntimicrobial Agents and Chemotherapy, 2012
- Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired PneumoniaAntimicrobial Agents and Chemotherapy, 2010
- Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumoniaBMC Pulmonary Medicine, 2009
- Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacinDiagnostic Microbiology and Infectious Disease, 2009
- Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumoniaDiagnostic Microbiology and Infectious Disease, 2008
- Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal InfectionsAntimicrobial Agents and Chemotherapy, 2008
- Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure InfectionsAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999